Celgene and Quanticel Pharmaceuticals announced a definitive share purchase agreement under which Celgene will acquire Quanticel Read the full story
Celgene and Quanticel Pharmaceuticals announced a definitive share purchase agreement under which Celgene will acquire Quanticel Read the full story
Celgene has entered into a strategic collaboration with MedImmune to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies Read the full story
Mesoblast has entered into an Agreement with Celgene Read the full story
Open Monoclonal Technology announced license that provides Celgene with unlimited access to OMT’s proprietary OmniRat, OmniMouse and OmniFlic platforms for generation of human antibody therapeutics Read the full story
Agios Pharmaceuticals announced that its collaboration partner Celgene has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120 Read the full story
Sutro Biopharma has entered a pharma deal and option agreement with Celgene to discover and develop antibodies and antibody drug conjugates. Read the full story
Bristol-Myers Squibb and Celgene become a pharma partners for evaluating the efficacy of combination treatment using OPDIVO and ABRAXANE. Read the full story
NanoString Technologies entered into a pharma deal with Celgene to develop a companion diagnostic assay using the nCounter Analysis System to support the clinical validation of REVLIMID for treatment of Diffuse Large B-Cell Lymphoma for $45 million. Read the full story
The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story
Celgene is a top pharmaceutical company, incorporated in Delaware and headquartered in Summit, New Jersey Read the full story